LONGEVITY & CELLULAR HEALTH / COMPARE
Three Molecules, Three Distances From the Evidence
Ranked by mechanism the order is one thing; ranked by human evidence it is almost the reverse. That mismatch is the most useful fact on this desk.
The short version
Comparing these three properly means comparing two separate things at once: how each molecule is thought to work, and how much human evidence actually stands behind it. The two rankings do not line up, and noticing that is worth more than any individual finding on this site.
By mechanism, MOTS-c is the most elegant — a peptide encoded in mitochondrial DNA, released during exercise, which travels into the nucleus and changes gene expression [11][12]. By human evidence, it is last: no interventional trial in people exists, and its human data are association measurements in patients [9].
NAD+ runs the other way. Its mechanism is the plainest of the three — a coenzyme that carries electrons and gets consumed by three families of enzymes [4] — and its evidence is by far the strongest, with randomized, placebo-controlled human trials showing that precursors reliably raise blood NAD+ and that some functional measures moved with it [2][3][5].
Epitalon sits at the extreme of both scales: the boldest claim, telomere lengthening, and the least controlled human data, a six-to-eight-year observational study with no randomization and no placebo [17].
The three side by side
| NAD+ | MOTS-c | Epitalon | |
|---|---|---|---|
| What it is | Redox coenzyme — not a peptide | 16-amino-acid mitochondrial-derived peptide | Synthetic 4-amino-acid pineal tetrapeptide |
| Where it comes from | Built and recycled by every cell via the salvage pathway | Encoded in mitochondrial DNA; released by muscle during exercise [11] | Synthesised to match the composition of a bovine pineal extract [13] |
| Main proposed mechanism | Electron carrier, plus substrate consumed by sirtuins, PARPs and CD38 [4] | Folate-cycle inhibition, AICAR accumulation, AMPK activation; nuclear translocation [10][12] | hTERT and telomerase upregulation; AANAT-driven melatonin synthesis [16][15] |
| Best human evidence | Randomized, placebo-controlled trials [2][3][5] | Observational biomarker association in patients [9] | Observational cohort, no randomization or placebo [17] |
| Human interventional trials | Yes | None | None to FDA or EMA standards |
| Regulatory status | Sold as a supplement; NMN's status contested; IV forms compounded | Research chemical; prohibited in elite sport | Research chemical; unapproved in the US, EU and UK [13] |
| Studied mainly for | Insulin sensitivity, metabolic and cardiac function [3][7] | Muscle glucose uptake, physical performance, atrophy prevention [8][11] | Telomere length, melatonin and circadian rhythm [14][15] |
| Biggest open question | Does raising the pool restore the functions it serves? [1] | Does an endogenous signal do anything when given from outside? | Does anything seen in culture happen in a person? |
Mechanism: three different levers
The three act on completely different parts of the maintenance problem, which is why they belong on one desk rather than in competition.
NAD+ is about supply. The molecule is a currency, not a message. It carries electrons through glycolysis, the TCA cycle and oxidative phosphorylation, and it is separately consumed as raw material by sirtuins, PARPs and CD38 [4]. The ageing hypothesis is an economic one: demand rises — CD38 activity climbs with age and inflammation [6] — while supply does not keep pace, and topping up the pool is meant to rebalance the account.
MOTS-c is about signalling. Nothing is being supplied; a message is being sent. The peptide inhibits the folate cycle, AICAR accumulates, AMPK switches on, and the cell reads that as a low-fuel state and behaves accordingly [10]. Under stress the peptide goes further and enters the nucleus, altering which genes are transcribed through NRF2 and related factors [12]. A 2024 study identified casein kinase 2 as a direct binding target, modulated in opposite directions in muscle and fat [8].
Epitalon is about a switch. The proposal is that a four-amino-acid sequence re-enables two things that decline with age: telomerase activity, through hTERT [16], and melatonin synthesis, through AANAT and pCREB in pineal cells [15]. Both are framed as normalisation rather than enhancement — restoring an axis rather than pushing it past baseline.
Evidence maturity: the ranking that matters
If a reader takes one thing from this page, it should be this ordering, because it is the one the marketing around these compounds most consistently obscures.
Tier one — randomized human trials exist. Only NAD+ precursors qualify. A multicentre, double-blind, placebo-controlled trial of oral NMN at 300-900 mg per day for 60 days raised blood NAD+ dose-dependently and improved walking distance and quality-of-life scores against placebo [2]. A ten-week trial of 250 mg per day of NMN improved muscle insulin sensitivity by clamp in prediabetic, postmenopausal women, with no change in body composition or HbA1c [3]. Eight weeks of nicotinamide riboside at 100-1000 mg per day raised whole-blood NAD+ by 22%, 51% and 142% with no significant adverse-event difference from placebo [5]. Even here the 2025 review concluded that human efficacy has been limited and tissue-level data remain sparse [1].
Tier two — human observation without intervention. MOTS-c and Epitalon both sit here, but not equally. The MOTS-c cohort of 94 haemodialysis patients was prospective and multicentre, and it measured a peptide the participants produced themselves [9]. The Epitalon cohort of 266 elderly people ran six to eight years, reported large mortality differences, and had no randomization and no placebo arm at all [17].
Tier three — cells and animals only. This is where nearly all the exciting material lives: the mouse performance results [11], the CK2 target work [8], the nuclear translocation experiments [12], the telomerase induction in fibroblasts [16][14], the pinealocyte melatonin findings [15]. None of it is worthless. None of it is a human outcome either.
What each is actually studied for
Stripping away what these compounds are marketed for leaves a much narrower and more specific list.
NAD+ is studied for metabolic and cardiac function. The concrete endpoints in the human record are blood NAD+ concentration, walking distance, quality-of-life scores [2] and muscle insulin sensitivity [3]. In tissue, the most recent significant work is cardiac: NAD+ repletion restoring the ketogenic enzyme HMGCS2, increasing fatty-acid oxidation and rescuing function in a heart-failure model, with a knockdown control confirming the mechanism [7].
MOTS-c is studied for skeletal muscle. Glucose uptake, prevention of atrophy, and physical performance in ageing animals are the recurring outcomes [8][11], with the peptide's exercise inducibility as the organising idea [11]. Its human appearances are as a risk biomarker rather than a treatment [9].
Epitalon is studied for telomere maintenance and the circadian neuroendocrine axis. Telomere elongation and hTERT induction in cultured human cells [16][14], melatonin synthesis in pineal cells [15], and an observational mortality association in elderly people [17].
None of the three is studied for the composite of "anti-ageing" that the category name suggests. Each has a narrow experimental record, and the breadth appears only in the retail description.
What this comparison does not settle
A comparison table is a device for holding things still, and these three are not still.
It does not settle whether the maintenance hypothesis is right. All three rest on the same underlying idea — that ageing partly reflects the erosion of routine cellular housekeeping, and that topping up the housekeeping might slow the erosion. The idea is plausible and the mechanisms are real; whether the intervention follows from the mechanism is unproven for every molecule here, and most explicitly stated for the best-evidenced one [1].
It does not settle safety over long periods, because nothing here has been studied over long periods in people. The NAD+ trials ran eight to ten weeks [3][5]; MOTS-c has no human interventional record at all; Epitalon's long human exposure comes from an uncontrolled cohort [17].
And it does not settle sourcing. Two of the three are research chemicals sold without pharmaceutical-grade quality control, which means the material itself is a variable the literature cannot account for.
What the comparison does settle is where each molecule stands today, which is enough to read the rest of this site — and enough to notice when a claim about one of them has quietly borrowed the evidence belonging to another.